Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Eligibility for neoadjuvant/adjuvant cisplatin‐based chemotherapy among radical cystectomy patients
Thompson, R. Houston, Boorjian, Stephen A. , Kim, Simon P. , Cheville, John C. , Thapa, Prabin , Tarrel, Robert, Dronca, Roxana , Costello, Brian A. , Frank, Igor

BJU International | June 13, 2013 | Volume: 113 | Issue: 5b | Pages: No page available

10.1111/bju.12274 | PMID 24006893 Get It

Objective To determine renal function eligibility for cisplatin‐based chemotherapy using our experience with radical cystectomy ( RC ) patients. Patients and Methods Using the M ayo C linic C ystectomy R egistry, we identified 768 patients treated with RC without neoadjuvant chemotherapy for urothelial carcinoma from 1980–2005. Glomerular filtration rate ( GFR ) was estimated using the C hronic K idney D isease E pidemiology C ollaboration ( CKD‐EPI ) equation and a value of ≥60 mL/min was considered eligible for cisplatin‐based chemotherapy. Factors associated with change in GFR (from preoperative to 3‐month postoperative) were assessed using linear regression. Results The median age was 68 years, while the median GFR was 60 mL/min both preoperatively and 3 months after RC . Overall, 405 (53%) patients had a GFR of <60 mL/min before surgery and 387 (50%) had a GFR of <60 mL/min at 3 months after RC . Patients with hydronephrosis (209 patients) had significantly lower preoperative GFRs than with patients without hydronephrosis (median 52 vs 62 mL/min, respectively; P < 0.001). Among the 363 patients with a GFR of ≥60 mL/min before RC , 91 (25%) had a decline in renal function to a GFR of <60 mL/min at 3 months after RC . In multivariable analyses, older age ( P < 0.001), higher preoperative GFR ( P < 0.001) and continent urinary diversion ( P = 0.011) were significantly associated with a negative change in GFR after RC . Conclusions Our results suggest that nearly half of patients undergoing RC are not eligible to receive perioperative cisplatin‐based chemotherapy based on renal function status. About a quarter of patients eligible for cisplatin before surgery are no longer eligible after RC . Certain patient characteristics and surgical factors are more likely to experience a negative change in GFR after RC and should be counselled accordingly.
Thyroxine and Triiodothyronine Content in Commercially Available Thyroid Health Supplements
Kang, Grace , Parks, Jonathan R., Fileta, Bader B., Chang, Audrey S., Abdel-Rahim, Maged, Burch, Henry B. , Bernet, Victor

Thyroid® | June 13, 2013 | Volume: 23 | Issue: 10 | Pages: 1233-1237

10.1089/thy.2013.0101 | PMID 23758055 Get It

Background: As defined by the Dietary Supplement Health and Education Act 1997, such substances as herbs and dietary supplements fall under general Food and Drug Administration supervision but have not been closely regulated to date. We examined the thyroid hormone content in readily available dietary health supplements marketed for “thyroid support.” Methods: Ten commercially available thyroid dietary supplements were purchased. Thyroid supplements were dissolved in 10 mL of acetonitrile and water with 0.1% trifloroacetic acid and analyzed using high-performance liquid chromatography for the presence of both thyroxine (T4) and triiodothyronine (T3) using levothyroxine and liothyronine as a positive controls and standards. Results: The amount of T4 and T3 was measured separately for each supplement sample. Nine out of 10 supplements revealed a detectable amount of T3 (1.3–25.4 μg/tablet) and 5 of 10 contained T4 (5.77–22.9 μg/tablet). Taken at the recommended dose, 5 supplements delivered T3 quantities of greater than 10 μg/day, and 4 delivered T4 quantities ranging from 8.57 to 91.6 μg/day. Conclusions: The majority of dietary thyroid supplements studied contained clinically relevant amounts of T4 and T3, some of which exceeded common treatment doses for hypothyroidism. These amounts of thyroid hormone, found in easily accessible dietary supplements, potentially expose patients to the risk of alterations in thyroid levels even to the point of developing iatrogenic thyrotoxicosis. The current study results emphasize the importance of patient and provider education regarding the use of dietary supplements and highlight the need for greater regulation of these products, which hold potential danger to public health.
Identification and proximal tubular localization of the Mg2+transporter, Slc41a1, in a seawater fish
Islam, Zinia, Hayashi, Naoko, Yamamoto, Yoko , Doi, Hiroyuki , Romero, Michael F. , Hirose, Shigehisa , Kato, Akira , Romero, Michael F , Kato, Akira

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | June 13, 2013 | Volume: 305 | Issue: 4 | Pages: R385-R396

10.1152/ajpregu.00507.2012 | PMID 23761638 Get It

The second most abundant cation in seawater (SW), Mg2+, is present at concentrations of ∼53 mM. Marine teleosts maintain plasma Mg2+concentration at 1–2 mM by excreting Mg2+into the urine. Urine Mg2+concentrations of SW teleosts exceed 70 mM, most of which is secreted by the renal tubular epithelial cells. However, molecular mechanisms of the Mg2+secretion have yet to be clarified. To identify transporters involved in Mg2+secretion, we analyzed the expression of fish homologs of the Slc41 Mg2+transporter family in various tissues of SW pufferfish torafugu ( Takifugu rubripes) and its closely related euryhaline species mefugu ( Takifugu obscurus). Takifugu genome contained five members of Slc41 genes, and only Slc41a1 was highly expressed in the kidney. Renal expression of Slc41a1 was markedly elevated when mefugu were transferred from fresh water (FW) to SW. In situ hybridization analysis and immunohistochemistry at the light and electron microscopic levels revealed that Slc41a1 is localized to vacuoles in the apical cytoplasm of the proximal tubules. These results suggest that pufferfish Slc41a1 is a Mg2+transporter involved in renal tubular transepithelial Mg2+secretion by mediating Mg2+transport from the cytosol to the vacuolar lumen, and support the hypothesis that Mg2+secretion is mediated by exocytosis of Mg2+-rich vacuoles to the lumen.
The Measles Virus Hemagglutinin β-Propeller Head β4-β5 Hydrophobic Groove Governs Functional Interactions with Nectin-4 and CD46 but Not Those with the Signaling Lymphocytic Activation Molecule
Mateo, Mathieu , Navaratnarajah, Chanakha K. , Syed, Sabriya A. , Cattaneo, Roberto

Journal of Virology | June 13, 2013 | Volume: 87 | Issue: 16 | Pages: 9208-9216

10.1128/jvi.01210-13 | PMID 23760251 Get It

ABSTRACT Wild-type measles virus (MV) strains use the signaling lymphocytic activation molecule (SLAM; CD150) and the adherens junction protein nectin-4 (poliovirus receptor-like 4 [PVRL4]) as receptors. Vaccine MV strains have adapted to use ubiquitous membrane cofactor protein (MCP; CD46) in addition. Recently solved cocrystal structures of the MV attachment protein (hemagglutinin [H]) with each receptor indicate that all three bind close to a hydrophobic groove located between blades 4 and 5 (β4-β5 groove) of the H protein β-propeller head. We used this structural information to focus our analysis of the functional footprints of the three receptors on vaccine MV H. We mutagenized this protein and tested the ability of individual mutants to support cell fusion through each receptor. The results highlighted a strong overlap between the functional footprints of nectin-4 and CD46 but not those of SLAM. A soluble form of nectin-4 abolished vaccine MV entry in nectin-4- and CD46-expressing cells but only reduced entry through SLAM. Analyses of the binding kinetics of an H mutant with the three receptors revealed that a single substitution in the β4-β5 groove drastically reduced nectin-4 and CD46 binding while minimally altering SLAM binding. We also generated recombinant viruses and analyzed their infections in cells expressing individual receptors. Introduction of a single substitution into the hydrophobic pocket affected entry through both nectin-4 and CD46 but not through SLAM. Thus, while nectin-4 and CD46 interact functionally with the H protein β4-β5 hydrophobic groove, SLAM merely covers it. This has implications for vaccine and antiviral strategies.
Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view
Ahlquist, David A. , Kisiel, John B.

Therapeutic Advances in Gastroenterology | June 13, 2013 | Volume: 6 | Issue: 5 | Pages: 371-380

10.1177/1756283x13487941 | PMID 24003338 Get It

Patients with inflammatory bowel disease (IBD) are at increased risk for colorectal cancer (CRC). Despite weak supporting evidence, important logistic barriers and high cost, colonoscopy is currently the only recommended approach to CRC surveillance in patients with IBD. As such, there is imperative to explore alternative or complementary strategies with potential to improve the efficiency and effectiveness of surveillance in IBD. Given our increasing understanding of tumorigenesis in IBD and the accompanying cascade of molecular alterations, there is a strong rationale to pursue biomarker assays for this application. Stool-based DNA testing with advanced technology has been shown to be highly discriminatory for detection of sporadic colorectal cancer and advanced precancers. In early observations, stool DNA testing also shows promise for the accurate detection of IBD-associated colorectal neoplasms. These findings raise important clinical and translational questions about how to best evaluate and develop this technology, and devise clinical algorithms that will complement colonoscopy to improve patient outcomes.
Comparison of virtual microscopy and glass slide microscopy among dermatology residents during a simulated in‐training examination
Brick, Katherine E., Sluzevich, Jason C. , Cappel, Mark A. , DiCaudo, David J. , Comfere, Nneka I. , Wieland, Carilyn N. , Sluzevich, Jason C

Journal of Cutaneous Pathology | June 12, 2013 | Volume: 40 | Issue: 9 | Pages: 807-811

10.1111/cup.12189 | PMID 23808673 Get It

AbstractBackgroundVirtual microscopy is increasingly being used in dermatopathology educational settings.ObjectiveThe objective is to evaluate diagnostic accuracy and attitudes between virtual microscopy and traditional glass slide microscopy among dermatology residents.MethodsA 48‐question dermatopathology examination was administered to 35 dermatology residents at three different dermatology residency training sites during the 2011–2012 academic year with half (n = 24) of the questions using the gold standard of glass slide microscopy and half (n = 24) using whole, scanned virtual slides. Correct number of questions using glass slides and virtual slides was evaluated. Participants were surveyed regarding previous experience with digital slide imaging; quality, ease of use, and speed of slide review; and overall microscopy preferences.ResultsOverall, diagnostic accuracy was better with glass slides than virtual slides (p = 0.01). However, no statistically significant difference was found in diagnostic accuracy of first‐year trainees (p > 0.99) or trainees with exposure to virtual microscopy greater than two times per month (p = 0.27). There was no overall personal preference for glass slide vs. virtual microscopy.LimitationsDifferent cases and questions were used for glass slides and virtual microscopy.ConclusionsDiagnostic accuracy with virtual microscopy is dependent on year of residency training and prior experience with virtual microscopy.
Acquired Epidermodysplasia Verruciformis in a Child with the Human Immunodeficiency Virus
Cowan, Katelyn R., Santiago, Tania M. González, Tollefson, Megha M.

Pediatric Dermatology | June 12, 2013 | Volume: 30 | Issue: 6 | Pages: No page available

10.1111/pde.12164 | PMID 23758597 Get It

AbstractEpidermodysplasia verruciformis (EDV) is a rare genodermatosis characterized by susceptibility to human papilloma virus (HPV) infection. An acquired form of EDV has been described in the setting of immunosuppression, including in patients with the human immunodeficiency virus (HIV). We present the case of an HIV‐positive, adopted Haitian boy who presented with EDV. Few cases of chidren with HIV and acquired EDV have been reported and are likely underrecognized.
Protamine Does Not Increase Risk of Stroke in Patients With Elective Carotid Stenting
Kallmes, David F. , Cloft, Harry J. , McDonald, Jennifer S. , Lanzino, Giuseppe

Stroke | June 12, 2013 | Volume: 44 | Issue: 7 | Pages: 2028-2030

10.1161/strokeaha.113.001188 | PMID 23760211 Get It

Background and Purpose— Reversal of anticoagulation with protamine might predispose to a higher risk of stroke in patients with carotid stenting. We evaluated a national, multihospital patient database to examine the risk of stroke in patients with carotid stenting receiving protamine compared with those who did not. Methods— The Premier Perspective database was used to identify patients who were electively hospitalized for carotid stenting from 2006 through 2011. The incidence of in-hospital mortality and morbidity was compared between patients who did and did not receive protamine after propensity score adjustment via 1:1 matching to reduce selection bias. Results— Of 6664 patients with carotid stenting treated at 193 hospitals, 556 (8%) received protamine on the day of the procedure. After matching by propensity score, patients who received protamine had a similar likelihood of stroke or transient ischemic attack ( P =0.77), in-hospital mortality ( P =0.12), discharge to long-term care ( P =0.15), and access site complications ( P =0.90) as compared with patients who did not receive protamine. Conclusions— Protamine administration is not associated with additional risk of adverse events after carotid stenting.
Risks and Benefits of Anticoagulation in Atrial Fibrillation
Cullen, Michael W. , Kim, Sunghee , Piccini, Jonathan P. , Ansell, Jack , Fonarow, Gregg C. , Hylek, Elaine M. , Singer, Daniel E. , Mahaffey, Kenneth W. , Kowey, Peter R. , Thomas, Laine , Go, Alan S. , Chang, Paul, Lópes, Renato D. , Peterson, Eric D. , Gersh, Bernard J.

Circulation: Cardiovascular Quality and Outcomes | June 12, 2013 | Volume: 6 | Issue: 4 | Pages: 461-469

10.1161/circoutcomes.113.000127 | PMID 23759473 Get It

Background— Patients with atrial fibrillation (AF) at the highest stroke risk derive the largest benefit from oral anticoagulation (OAC). Those with the highest stroke risk have been paradoxically less likely to receive OAC. This study assessed the association between stroke and bleeding risk on rates of OAC. Methods and Results— We analyzed OAC use among 10 098 patients with AF from 174 community-based outpatient practices enrolled in 2010–2011 in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). OAC was defined as warfarin or dabigatran use at study enrollment. Stroke and bleeding risk were calculated using congestive heart failure, hypertension, age, diabetes mellitus, prior stroke (CHADS 2 ), and anticoagulation and risk factors in AF (ATRIA) scores, respectively. The mean subject age was 73 years; 58% were men. Overall, 76% of patients received OAC (71% warfarin and 5% dabigatran). The use of OAC increased among those with higher CHADS 2 scores, from 53% for CHADS 2 =0 to 80% for CHADS 2 ≥2 ( P <0.001). OAC use fell slightly with increasing ATRIA bleeding risk score, from 81% for ATRIA=3 to 73% for ATRIA≥5 ( P <0.001). A significant interaction existed between ATRIA and CHADS 2 scores ( P =0.021). Among those with low bleeding risk, use of OAC increased significantly with increasing stroke risk. Among those with high bleeding risk, CHADS 2 stroke risk had a smaller impact on use of OAC. Conclusions— In community-based outpatients with AF, use of OAC was high and driven by not only predominantly stroke but also bleeding risk. Stroke risk significantly affects OAC use among those with low bleeding risk, whereas those with high bleeding risk demonstrate consistently lower use of OAC regardless of stroke risk.